ESPE Abstracts (2022) 95 P1-50

ESPE2022 Poster Category 1 Diabetes and Insulin (86 abstracts)

An Evaluation of MiniMed™ 780G System Performance in Childhood: A Single Center Experience from Turkey

Elif Eviz 1 , R. Gul Yesiltepe Mutlu 1 , Ecem Can 2 , Tugba Gokce 2 , Serra Muradoglu 2 & Sukru Hatun 1

36 views


1Koç University, Istanbul, Turkey; 2Koç University Hospital, Istanbul, Turkey


Introduction: Automated insulin delivery systems provide significant improvement in the time in range(TIR) centered diabetes care. This study analyzes the real-word performance of Minimed 780G™system-Advanced Hybrid Closed Loop(AHCL) in children from a single center.

Methods: Of the 93 children started to use AHCL between January 2021 and April 2022, 64 whose data could be accessed were included. 3,6,9 and 12 month-data were analyzed in terms of the proportion of users achieving recommended glucose management indicator (GMI<7.0%), TIR (70-180 mg/dL >70%) and time below range(TBR<5%) goals. In a second analysis, data of the children previously treated with multiple daily injections (MDI) (group-1, n:23) and with insulin pumps (group-2, n:39) were analyzed regarding glycemic profile before and after AHCL.

Results: At the baseline mean TIR, TBR<70 and HbA1c were 72.7±11.7%, 4±4.5% and 7.3±0.9% while they were 80.1±8.7%, 3.4±3% and 6.8±0.8% respectively at 3-month. TIR increased by 7.4% at 3-month, compared to baseline (P:0.001). At 3-month, 88% of the participants achieved TIR>70% goal, 80.4% achieved TIR >70% and GMI<7% and TBR<5% goals. No significant difference was noted between 3-6-9 and 12th month TIR percentages (80%, 79%, 81%, 82%, p:0.122). In group-1 and group-2, the increase in TIR from baseline to 3-month were 13%, 6%, respectively (P1:0.01; p2:0.017). The increase in TIR at 3-month in Group-1 was significantly higher than in Group-2 (P 0.014).

Table 1. Glycemic metric values at 1-year follow-up before and after AHCL use
  Baseline(n:33) 3-month(n:58) 6-month(n: 41) 9-month (n:34) 12-month (n:24)
Automode(%) N/A 96.3±8.1 95.6±6.9 97±4 95.2±7.7
TIR(%) 72.7±11.7 80.1±8.7 79.1±9.2 81.4±7.8 82.1±7
TAR>180(%) 18.8±8.4 13.8±6.5 15±6.6 13.5±5.3 13.3±5.3
TAR >250(%) 4.2±4.6 2.6±2.8 2.8±2.7 2.5±2.8 2±2.2
TBR<70(%) 4±4.5 3.4±3 2.4±2.2 2.2±1.7 2.5±1.8
CV(%) 33.7±6.1 33.7±5.1 33±4.2 32.7±6 31.8±7.3
GMI(%) N/A 7±3.8 6.6±0.2 6.5±0.2 6.5±0.28
HbA1c (%) 7.3±0.9 6.8±0.8 6.8±0.4 7.1±0.8 6.8±0.5
TIR of>%70 60 87.7 82.9 94.1 95.8
3 goals (TIR>70%+GMI<7%+TBR<5) N/A 80.4 77.5 85.3 87
*Linear regression model was used in the analysis of the data

Conclusion: AHCL is a reliable system for achieving and maintaining glycemic goals, mainly TIR >70%goal in children. The improvement is more prominent in the children previously treated with MDI.

Volume 95

60th Annual ESPE (ESPE 2022)

Rome, Italy
15 Sep 2022 - 17 Sep 2022

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.